文献速递神经肿瘤

TRIM44通过AKT/p21/p27通路调控胶质瘤细胞增殖与细胞周期

TRIM44 is indispensable for glioma cell proliferation and cell cycle progression through AKT/p21/p27 signaling pathway.
PubMed 文献 · J Neurooncol · 2019-10-11

该研究探讨TRIM44在胶质瘤中的表达及功能,发现TRIM44在胶质瘤细胞中显著升高且高表达与不良预后相关;敲低TRIM44可抑制胶质瘤细胞增殖、迁移、诱导细胞周期紊乱和凋亡,并在裸鼠移植瘤模型中抑制肿瘤生长,机制涉及AKT/p21/p27通路。

要点

  • TRIM44在胶质瘤细胞中显著升高,高表达与患者不良预后相关。
  • 敲低TRIM44抑制胶质瘤细胞增殖、迁移并诱导细胞周期紊乱和凋亡。
  • TRIM44失活通过AKT/p21/p27通路发挥作用,可能成为治疗靶点。

核心结论

  • TRIM44与胶质瘤的致癌潜能相关,靶向TRIM44可能有益于胶质瘤治疗。

研究设计与样本

  • 采用定量PCR和western blot评估胶质瘤细胞中TRIM44表达。
  • 通过Brdu掺入和集落形成实验检测细胞增殖。
  • 采用Caspase 3染色和FACS分析检测TRIM44敲低诱导的胶质瘤细胞凋亡。
  • 使用BALB/c裸鼠移植瘤模型及免疫组化染色探索TRIM44缺失对胶质瘤体内生长的影响。
  • 通过western blot检测p21、p27和AKT以提示TRIM44调控AKT通路的可能作用。

主要发现

  • TRIM44在胶质瘤细胞中显著升高,高表达与胶质瘤患者不良预后相关。
  • shRNA敲低TRIM44在体外抑制胶质瘤细胞增殖、迁移,诱导细胞周期紊乱及细胞凋亡。
  • TRIM44失活明显抑制移植瘤模型中的肿瘤生长。
  • TRIM44缺陷细胞中负性细胞周期调节因子p21/p27显著上调,而p21/p27的主要调节因子AKT失活。

临床怎么用

  • TRIM44高表达与胶质瘤不良预后相关,可作为预后评估的潜在生物标志物。
  • 靶向TRIM44可能通过AKT/p21/p27通路抑制胶质瘤增殖,为治疗提供新方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Glioma is one of the lethal cancers which needs effective therapeutic target. TRIM44 has been found playing a carcinogenic role in human tumors such as breast cancer and ovarian cancer. However, the pathophysiological significance of TRIM44 in glioma is still unclear. METHODS: Quantitative-PCR and western blot were used to assess the expression of TRIM44 in glioma cells. For cell proliferation, Brdu incorporation and colony formation assays were performed. By Caspase 3 staining and FACS analysis, we revealed that TRIM44 knockdown induced glioma cell apoptosis. A BALB/c nude mouse xenograft model and following immunohistochemical (IHC) staining enables us to explore the effect of TRIM44 deletion on glioma growth in vivo. Western blot of p21, p27 and AKT indicated the possible role of TRIM44 in regulation AKT pathway in glioma. RESULTS: TRIM44 was significantly elevated in glioma cells, and high expression of TRIM44 is related to poor prognostic of glioma patients. TRIM44 knockdown by shRNAs inhibit glioma cell proliferation, migration, induced cell cycle disruption and further cellular apoptosis in vitro. As well, TRIM44 inactivation obviously inhibit tumor growth in xenograft model. Furthermore, the negative cell cycle regulators p21/p27 are significantly upregulated, while AKT which is known as the main regulator of p21/p27 is inactivated in TRIM44-dificient cells. These results suggested that TRIM44 inactivation disrupted cell cycle progression and inhibit cell proliferation through AKT/p21/p27 pathway in glioma. CONCLUSION: TRIM44 was associated with oncogenic potential of glioma. Targeting TRIM44 might be beneficial for glioma therapy.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Zhou X, Yang Y, Ma P, et al. TRIM44 is indispensable for glioma cell proliferation and cell cycle progression through AKT/p21/p27 signaling pathway. J Neurooncol. 2019. PMID: 31605296. doi:10.1007/s11060-019-03301-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。